3 research outputs found
Clinical patterns of endothelial damage and thrombotic events in two patients with COVIDâ19: A case report
Abstract Endotheliopathy causes COVIDâ19 conflicting complications
Cancer patients and targeted therapy during COVIDâ19 pandemic: A descriptive case series study
Abstract To evaluate the effectiveness of targeted therapy on preventing or treating COVIDâ19, in this study, we want to share our experience about 14 patients (nine women, five men; average age, 59âyears) who were treated with targeted therapy due to their underlying malignant disorders in our center
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study
BACKGROUND
Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19.
METHODS
In this multi-center study, we followed 1529 COVID-19 patients for at least 45Â days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45Â days of hospital discharge.
RESULTS
Of 1529 COVID-19 patients discharged from hospital, a total of 228 (14.9%) reported potential signs or symptoms of PE or DVT and were seen for an in-hospital visit. Of these, 13 and 12 received Doppler ultrasounds or pulmonary CT angiography, respectively, of whom only one patient was diagnosed with symptomatic PE. Of 51 (3.3%) patients who died after discharge, two deaths were attributed to VTE corresponding to a 45-day cumulative rate of symptomatic VTE of 0.2% (95%CI 0.1%-0.6%; n = 3). There was no evidence of acute respiratory distress syndrome (ARDS) in these patients. Other deaths after hospital discharge included myocardial infarction (n = 13), heart failure (n = 9), and stroke (n = 9).
CONCLUSIONS
We did not observe a high rate of symptomatic VTE in COVID-19 patients after hospital discharge. Routine extended thromboprophylaxis after hospitalization for COVID-19 may not have a net clinical benefit. Randomized trials may be warranted